Telithromycin 800 mg once daily for seven to ten days is an effective and well-tolerated treatment for community-acquired pneumonia

Carbon, C; Moola, S.; Velancsics, I.; Leroy, Bruno; Rangaraju, M.; Decosta, P.

doi:10.1046/j.1469-0691.2003.00678.x

Cited by 39 publications

(21 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Our in-vitro results, with telithromycin, are also consistent with recent clinical data, which demonstrated excellent activity in the treatment of community-acquired pneumonia [26,27]. Based on the promising in vitro results in this study, clinical trials assessing the efficacy of the new respiratory tract quinolones and ketolides for the treatment of Legionnaire's disease due L. pneumophila and other species are indicated.…”

Section: Discussionsupporting

confidence: 89%

Comparative activity of quinolones, macrolides and ketolides against Legionella species using in vitro broth dilution and intracellular susceptibility testing

Stout

Sens

Mietzner

et al. 2005

International Journal of Antimicrobial Agents

View full text Add to dashboard Cite

Section: Discussionsupporting

confidence: 89%

Comparative activity of quinolones, macrolides and ketolides against Legionella species using in vitro broth dilution and intracellular susceptibility testing

Stout

Sens

Mietzner

et al. 2005

International Journal of Antimicrobial Agents

View full text Add to dashboard Cite

“…The results of the present pooled analysis are consistent with the overall clinical and bacteriological efficacy (91.2 and 90.4%, respectively) observed in the trials of patients with CAP treated with a once-daily oral dose of telithromycin 800 mg [14,15,16,17,18,19,20]; Aventis,unpubl. data[].…”

Section: Discussionsupporting

confidence: 89%

Efficacy of Telithromycin in Community-Acquired Pneumonia Caused by Pneumococci with Reduced Susceptibility to Penicillin and/or Erythromycin

Rensburg

Fogarty²,

Kohno³

et al. 2005

Chemotherapy

Self Cite

View full text Add to dashboard Cite

Background: The efficacy of oral telithromycin was assessed in patients with community-acquired pneumonia (CAP) caused by Streptococcus pneumoniae with reduced susceptibility to penicillin and/or erythromycin. Methods: Patients with CAP who had received telithromycin 800 mg once daily for 5 or 7–10 days (n = 2,289) in eight phase III clinical trials, or telithromycin 800 mg once daily for 7 days (n = 50) in a phase II study were included in this pooled analysis. Patients with S. pneumoniae as the cause of infection were identified, with particular focus on those infected with strains with reduced susceptibility to penicillin (intermediate, minimal inhibitory concentration (MIC) 0.12–1.0 mg/l; resistant, MIC ≧2.0 mg/l) and/or resistance to erythromycin (MIC ≧1.0 mg/l). Per-protocol clinical and bacteriological outcomes were assessed 7–14 days post-therapy in the phase III studies, and at 7–21 days post-therapy or at the end of therapy in the phase II study. Results: Of the 327 telithromycin-treated patients with S. pneumoniae infection, 61 (19%) were infected with strains with reduced susceptibility to penicillin and/or erythromycin. Clinical cure and bacterial eradication rates in these patients were 91.8% (56/61) and 93.4% (57/61), respectively. Corresponding clinical cure and bacterial eradication rates overall for all isolates of pneumococci were 94.5% (309/327) and 96.0% (314/327), respectively. All isolates with reduced susceptibility to penicillin and/or erythromycin were susceptible to telithromycin (MIC ≤1.0 mg/l). Conclusion: These results indicate that telithromycin is an effective oral antibacterial for the treatment of CAP caused by pneumococci with reduced susceptibility to penicillin and/or erythromycin.

show abstract

“…Overall, azithromycin and the investigational ketolide cethromycin (ABT-773) are the most potent drugs against M. pneumoniae in terms of MICs (436). Recently published clinical trials evaluating the investigational ketolide telithromycin alone (57) or in comparison with the fluoroquinolone trovafloxacin (336) for treatment of pneumonia in adults demonstrated that this ketolide produced clinical cure rates of 100 and 93.3%, respectively, for persons whose infection was due to M. pneumoniae.…”

Section: Treatment Of Infections Due To M Pneumoniaementioning

confidence: 99%

Mycoplasma pneumoniaeand Its Role as a Human Pathogen

2004

View full text Add to dashboard Cite

Mycoplasma pneumoniae is a unique bacterium that does not always receive the attention it merits considering the number of illnesses it causes and the degree of morbidity associated with it in both children and adults. Serious infections requiring hospitalization, while rare, occur in both adults and children and may involve multiple organ systems. The severity of disease appears to be related to the degree to which the host immune response reacts to the infection. Extrapulmonary complications involving all of the major organ systems can occur in association with M. pneumoniae infection as a result of direct invasion and/or autoimmune response. The extrapulmonary manifestations are sometimes of greater severity and clinical importance than the primary respiratory infection. Evidence for this organism's contributory role in chronic lung conditions such as asthma is accumulating. Effective management of M. pneumoniae infections can usually be achieved with macrolides, tetracyclines, or fluoroquinolones. As more is learned about the pathogenesis and immune response elicited by M. pneumoniae, improvement in methods for diagnosis and prevention of disease due to this organism may occur

show abstract

Telithromycin 800 mg once daily for seven to ten days is an effective and well-tolerated treatment for community-acquired pneumonia

Abstract: An oral dose of telithromycin 800 mg once daily for seven to ten days is an effective and well-tolerated first-line treatment for mild to moderate CAP in adults.

Cited by 39 publications

References 30 publications

Comparative activity of quinolones, macrolides and ketolides against Legionella species using in vitro broth dilution and intracellular susceptibility testing

Comparative activity of quinolones, macrolides and ketolides against Legionella species using in vitro broth dilution and intracellular susceptibility testing

Efficacy of Telithromycin in Community-Acquired Pneumonia Caused by Pneumococci with Reduced Susceptibility to Penicillin and/or Erythromycin

Mycoplasma pneumoniaeand Its Role as a Human Pathogen

Contact Info

Product

Resources

About